Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

James Saino

Pediatrics Cordova, TN Medical Doctor

NPI 1144332842 CMS profile 6846

1172 Vickery Ln, Cordova, TN 38016

Open in the dashboard

General payments

$4,028

300 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, James Saino of Cordova, TN is reported in the CMS Open Payments database as having received $4,028 across 300 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $471 52
2022 General $576 57
2021 General $789 59
2020 General $866 55
2019 General $1,326 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Saino
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to James Saino were reported at $0. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year James Saino Pediatrics median Middle half National median
2019 $1,326 $86 $31–$183 $163
2020 $866 $49 $22–$110 $114
2021 $789 $68 $27–$158 $132
2022 $576 $77 $30–$173 $149
2023 $471 $88 $33–$190 $160
2024 $0 $94 $34–$206 $164
2025 $0 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Tris Pharma Inc $1,669 186 payments
  2. Pfizer Inc. $356 19 payments
  3. GlaxoSmithKline, LLC. $344 12 payments
  4. Ironshore Pharmaceuticals Inc. $314 10 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $278 13 payments
  6. Supernus Pharmaceuticals, Inc. $191 4 payments
  7. Arbor Pharmaceuticals, Inc. $186 15 payments
  8. Adlon Therapeutics L.P. $181 9 payments
  9. Merck Sharp & Dohme Corporation $177 11 payments
  10. Neos Therapeutics, LP $134 9 payments
  11. Other $200 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $4,028 300 payments
Products named General payments · program years 2019–2023
  1. Dyanavel XR Adhd $867 66 payments
  2. Quillivant $438 30 payments
  3. VYVANSE $345 17 payments
  4. BEXSERO $344 12 payments
  5. Quillichew ER $336 21 payments
  6. Dyanavel XR Adhd $313 60 payments
  7. EUCRISA $295 15 payments
  8. Jornay PM 20mg capsules (Bottle of 100) $236 6 payments
  9. ADHANSIA XR $181 9 payments
  10. GARDASIL 9 $152 9 payments
  11. Other $1,714 109 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

300 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record